Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BCI · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BCI treatment | ACTIVE_COMPARATOR | BCI treatment will commence during the week of the Baseline. |
| Wait-list control | OTHER | BCI treatment will commence 8 weeks after Baseline |
| BCI pilot arm | EXPERIMENTAL | This is a experimental arm to test out the safety and effectiveness of BCI in improving ADHD symptoms. This pilot arm is necessary as the BCI device, incorporating dry electrode sensors and intervention game, is newly developed and have not been tested out in children with ADHD. This preliminary study will also allow us to test out the treatment protocol (24 sessions of BCI training over 8 weeks) to see if it is efficacious. |
| Name | Type | Description |
|---|---|---|
| BCI | DEVICE | 24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters. |
Inclusion Criteria: * DSM-IV-TR criteria for ADHD, either the combined or inattentive subtype, based on the Diagnostic Interview Schedule for Children (CDISC; Schaffer et al., 2000) Exclusion Criteria: * Present or history of medical treatment with stimulant medication and Atomoxetine * Co-morbid...
BCI is an investigational intervention being studied for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). It is currently in Phase 2 clinical development. The drug is being evaluated for its potential to address symptoms of ADHD, though it is not yet approved by regulatory authorities.
BCI is being developed by National Healthcare Corp., a company listed on the stock exchange under the ticker symbol NHC. The company is conducting clinical research to evaluate the safety and efficacy of BCI for the treatment of Attention Deficit Hyperactivity Disorder.
BCI is currently in Phase 2 clinical development. It is an investigational drug being studied for Attention Deficit Hyperactivity Disorder. The Phase 2 trial has been completed, and the drug is not yet approved by regulatory agencies. Further clinical studies may be needed to establish its safety and efficacy.
BCI has been studied in one clinical trial, identified as NCT01344044. This Phase 2 trial, titled 'Brain-Computer Interface (BCI) Based Intervention for Attention Deficit Hyperactivity Disorder (ADHD)', was completed and enrolled 192 participants in Singapore. The trial included children aged 6 years and older with ADHD.
BCI is the drug name used in the clinical trial, which is described as a brain-computer interface based intervention. The trial title refers to BCI as an intervention for ADHD, suggesting it may involve a technology-based approach rather than a traditional pharmaceutical. However, the specific mechanism of action is not disclosed.